Skip to main content

Narcolepsy Type 1

3
Pipeline Programs
4
Companies
13
Clinical Trials
7 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Alkermes
AlkermesDUBLIN 4, Ireland
1 program
1
ALKS 2680Phase 35 trials
Active Trials
NCT07540897Recruiting150Est. Jul 2027
NCT07502443Recruiting176Est. Jun 2027
NCT07455383Recruiting150Est. Jun 2027
+2 more trials
NLS Pharmaceutics
NLS PharmaceuticsSwitzerland - Zurich
1 program
1
NLS-2Phase 31 trial
Active Trials
NCT05914194Unknown48Est. Jul 2025
Centessa Pharmaceuticals
3 programs
1
cleminorextonPhase 2/31 trial
ORX750PHASE_21 trial
ORX750PHASE_21 trial
Active Trials
NCT06752668Recruiting248Est. Dec 2026
NCT07096674Recruiting90Est. Apr 2026
NCT07598708Recruiting222Est. Dec 2027
Takeda
TakedaTOKYO, Japan
2 programs
TAK-861PHASE_21 trial
TAK-861PHASE_31 trial
Active Trials
NCT05687903Completed112Est. Dec 2023
NCT06505031Completed105Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
AlkermesALKS 2680
AlkermesALKS 2680
AlkermesALKS 2680
TakedaTAK-861
NLS PharmaceuticsNLS-2
Centessa Pharmaceuticalscleminorexton
AlkermesALKS 2680
Centessa PharmaceuticalsORX750
AlkermesALKS 2680
Centessa PharmaceuticalsORX750
AlkermesALKS 2680
AlkermesALKS 2680
TakedaTAK-861

Clinical Trials (13)

Total enrollment: 2,398 patients across 13 trials

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Start: Aug 2026Est. completion: Jul 2027150 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Start: Apr 2026Est. completion: Jun 2027176 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Start: Apr 2026Est. completion: Jun 2027150 patients
Phase 3Recruiting

A Study of TAK-861 in People With Narcolepsy Type 1

Start: Oct 2024Est. completion: Jun 2025105 patients
Phase 3Completed

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1

Start: Jul 2024Est. completion: Jul 202548 patients
Phase 3Unknown

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

Start: May 2026Est. completion: Dec 2027222 patients
Phase 2/3Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Start: Jan 2025Est. completion: Jun 2030786 patients
Phase 2/3Recruiting

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Start: Aug 2025Est. completion: Apr 202690 patients
Phase 2Recruiting

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Start: May 2025Est. completion: Nov 2026126 patients
Phase 2Active Not Recruiting

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Start: Dec 2024Est. completion: Dec 2026248 patients
Phase 2Recruiting

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

Start: Jul 2024Est. completion: Nov 202593 patients
Phase 2Completed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Start: Mar 2024Est. completion: Jul 202592 patients
Phase 2Completed

A Study of TAK-861 in Participants With Narcolepsy Type 1

Start: Jan 2023Est. completion: Dec 2023112 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
7 actively recruiting trials targeting 2,398 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.